HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
HMG-CoA reductase inhibitors (statins) are widely prescribed and recommended as first-line therapy for most patients with hypercholesterolemia or established coronary heart disease. However, there is interpatient variability in lipid-lowering response to statins that is not explained by initial cholesterol levels and inadequate dosing alone. Genetic polymorphisms may contribute. This review discusses the potential contribution of polymorphisms in genes encoding proteins involved in drug metabolism and transport, cholesterol biosynthesis, lipid metabolism and others to lipid responses to statins.